InfuSystem Holdings (INFU) Cash from Financing Activities (2010 - 2026)
InfuSystem Holdings (INFU) reported Cash from Financing Activities of -$790000.0 for Q1 2026, down 142.47% on a YoY basis from $1.9 million in Q1 2025, and up 70.77% quarter-over-quarter from -$2.7 million in Q4 2025.
InfuSystem Holdings (INFU) Cash from Financing Activities (2010 - 2026) Analysis & Trends
InfuSystem Holdings has reported Cash from Financing Activities for 17 years, with the latest figure at -$790000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 142.47% year-over-year to -$790000.0; the trailing twelve-month figure through Mar 2026 stood at -$17.6 million (down 209.15% YoY), and the FY2025 full-year result was -$15.0 million, down 116.05% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$790000.0, up from -$2.7 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $3.7 million in Q2 2024, with the low at -$8.0 million in Q3 2025.
- Historically, Cash from Financing Activities has averaged -$2.0 million across 5 years, with a median of -$1.7 million in 2022.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities tumbled 4117.35% — and 2024, when it surged 1679.15%.
- InfuSystem Holdings' Cash from Financing Activities stood at -$1.7 million in 2022, then tumbled by 107.01% to -$3.5 million in 2023, then slipped by 27.4% to -$4.5 million in 2024, then soared by 40.13% to -$2.7 million in 2025, then soared by 70.77% to -$790000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$790000.0 (Q1 2026), -$2.7 million (Q4 2025), and -$8.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | -2.09 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -26.93 Mn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | -25.00 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | -97.90 Mn |
| 10 | InfuSystem Holdings | 189.78 Mn | 187.68 Mn | 19.68 Mn | -790,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -790,000.00 |
| Mar 31, 2026 | -790,000.00 |
| Dec 31, 2025 | -2.70 Mn |
| Dec 31, 2025 | -2.70 Mn |
| Sep 30, 2025 | -8.01 Mn |
| Sep 30, 2025 | -8.01 Mn |
| Jun 30, 2025 | -6.11 Mn |
| Jun 30, 2025 | -6.11 Mn |
| Mar 31, 2025 | 1.86 Mn |
| Mar 31, 2025 | 1.86 Mn |
| Dec 31, 2024 | -4.52 Mn |
| Dec 31, 2024 | -4.52 Mn |
| Sep 30, 2024 | -6.75 Mn |
| Sep 30, 2024 | -6.75 Mn |
| Jun 30, 2024 | 3.71 Mn |
| Jun 30, 2024 | 3.71 Mn |
| Mar 31, 2024 | 632,000.00 |
| Mar 31, 2024 | 632,000.00 |
| Dec 31, 2023 | -3.54 Mn |
| Dec 31, 2023 | -3.54 Mn |